{"id":"fulvestrant-injectable-product","rwe":[],"tags":[],"safety":{"drugInteractions":[{"drug":"Warfarin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Tamoxifen","action":"Avoid","effect":"Decreased efficacy of fulvestrant"},{"drug":"Estrogen-containing products","action":"Avoid","effect":"Decreased efficacy of fulvestrant"},{"drug":"Aromatase inhibitors","action":"Avoid","effect":"Decreased efficacy of fulvestrant"},{"drug":"CYP3A4 inhibitors","action":"Monitor","effect":"Increased fulvestrant plasma concentrations"},{"drug":"CYP3A4 inducers","action":"Monitor","effect":"Decreased fulvestrant plasma concentrations"}],"contraindications":["Pregnancy, nursing mothers, and women of childbearing potential not using effective contraception."]},"trials":[],"_chembl":null,"aliases":[],"company":"Pfizer","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=fulvestrant-injectable-product","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:57:10.549415+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:57:18.232364+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-19T23:57:10.567856+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=fulvestrant-injectable-product","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:57:19.006107+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4760678/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:57:19.963320+00:00"}},"allNames":"fulvestrant injectable product","offLabel":[],"timeline":[],"_dailymed":null,"aiSummary":"Fulvestrant Injectable Product is a marketed drug by Pfizer Inc. It is used for advanced breast cancer in postmenopausal women with disease progression following prior therapy. The drug is also indicated for hormone receptor-positive metastatic breast cancer in patients with disease progression on or after prior chemotherapy or endocrine therapy and chemotherapy. There are 57 trials and 0 publications available for this drug. The revenue and mechanism of action are not specified. As a marketed drug, it has commercial significance and pipeline developments.","brandName":"Fulvestrant Injectable Product","ecosystem":[],"isGeneric":true,"mechanism":{"target":"estrogen receptor","novelty":"best-in-class","modality":"peptide","drugClass":"estrogen receptor degrader","explanation":"","oneSentence":"","technicalDetail":"Fulvestrant is a 29-amino acid peptide that selectively binds to the estrogen receptor, leading to its degradation through the ubiquitin-proteasome pathway. This results in a decrease in estrogen receptor-positive breast cancer cell growth and proliferation. The mechanism of action of fulvestrant is distinct from other endocrine therapies, such as aromatase inhibitors and selective estrogen receptor modulators."},"_companyIR":{"url":"https://www.pfizer.com/investors","revenueRefs":[],"pipelineRefs":[]},"_scrapedAt":"2026-03-27T23:28:38.653Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"commercial":{"annualCostUS":"Generic pricing varies by manufacturer","genericStatus":"Generic — off-patent","peakSalesEstimate":"Not publicly reported"},"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=fulvestrant-injectable-product","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=fulvestrant-injectable-product","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://www.ebi.ac.uk/chembl/","fields":["molecular"],"source":"ChEMBL (EMBL-EBI)"},{"id":4,"url":"https://www.ema.europa.eu/","fields":["regulatoryStatus"],"source":"European Medicines Agency (EMA)"},{"id":5,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"}],"_tgaChecked":true,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:57:22.132470+00:00","fieldsConflicting":1,"overallConfidence":0.8},"_whoChecked":true,"biosimilars":[],"competitors":[{"name":"Arimidex","company":"AstraZeneca","advantage":"Oral administration, competitive efficacy in hormone receptor-positive breast cancer","genericName":"anastrozole"},{"name":"Femara","company":"Novartis","advantage":"Oral administration, strong track record in postmenopausal women with breast cancer","genericName":"letrozole"},{"name":"Aromasin","company":"Pfizer","advantage":"Oral administration, effective in advanced breast cancer and as adjuvant therapy","genericName":"exemestane"}],"genericName":"fulvestrant-injectable-product","indications":{"approved":[{"name":"Advanced breast cancer in postmenopausal women with disease progression following prior therapy","regulator":"FDA"},{"name":"Advanced breast cancer in hormone receptor-positive metastatic breast cancer in patients with disease progression on or after prior chemotherapy","regulator":"FDA"},{"name":"Advanced breast cancer in hormone receptor-positive metastatic breast cancer in patients with disease progression on or after prior endocrine therapy and prior chemotherapy in the metastatic setting","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"_mhraChecked":true,"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT07038369","phase":"PHASE1","title":"A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations","status":"ACTIVE_NOT_RECRUITING","sponsor":"Atavistik Bio, Inc","startDate":"2025-07-29","conditions":"Advanced Solid Tumors, Breast Cancer, Breast Carcinoma","enrollment":134},{"nctId":"NCT03424005","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2018-03-30","conditions":"Metastatic Breast Cancer","enrollment":792},{"nctId":"NCT06736704","phase":"PHASE1, PHASE2","title":"SNV4818 in Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Pikavation Therapeutics, Inc.","startDate":"2025-02-20","conditions":"Advanced Solid Tumors","enrollment":320},{"nctId":"NCT01560416","phase":"PHASE2","title":"Fulvestrant With or Without Ganetespib in HR+ Breast Cancer","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2012-06","conditions":"Breast Cancer","enrollment":50},{"nctId":"NCT06995482","phase":"PHASE1","title":"Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of KSHN001034 in Healthy Postmenopausal Female Volunteers","status":"RECRUITING","sponsor":"Kashiv BioSciences, LLC","startDate":"2025-08-18","conditions":"Healthy Postmenopausal Women","enrollment":40},{"nctId":"NCT05305924","phase":"PHASE2","title":"Fulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer","status":"RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2021-02-25","conditions":"ER-Positive Breast Cancer, HER2-negative Breast Cancer","enrollment":28},{"nctId":"NCT07366632","phase":"PHASE1","title":"A Study of Single Dose of BL0175 in Postmenopausal Women","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Best-Link Bioscience, LLC","startDate":"2026-01-26","conditions":"Postmenopausal Women","enrollment":27},{"nctId":"NCT03289039","phase":"PHASE2","title":"Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast Cancer","status":"TERMINATED","sponsor":"Dana-Farber Cancer Institute","startDate":"2017-10-25","conditions":"Breast Cancer","enrollment":21},{"nctId":"NCT07340619","phase":"PHASE2","title":"Clinical Trial Evaluating the Biological Activity of a New Drug Identified as Prifetrastat (PF-07248144), Combined With Fulvestrant for the Treatment of Patients With Hormone Receptor Positive (HR+) and HER2 Negative (HER2-) Breast Cancer Extended to Other Organs.","status":"NOT_YET_RECRUITING","sponsor":"UNICANCER","startDate":"2026-05-18","conditions":"Metastatic (Stage IV) Melanoma","enrollment":51},{"nctId":"NCT03056755","phase":"PHASE2","title":"Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2017-08-29","conditions":"Breast Cancer","enrollment":383},{"nctId":"NCT07330544","phase":"PHASE2","title":"A Phase II Clinical Study Evaluating Entinostat With or Without Anlotinib + Fulvestrant for the Treatment of Hormone Receptor (HR) -Positive, Human Epidermal Growth Factor Receptor-2 (HER-2) -Negative Advanced Breast Cancer That Relapsed or Progressed After Endocrine Therapy","status":"RECRUITING","sponsor":"Zhejiang Cancer Hospital","startDate":"2025-11-24","conditions":"Breast Cancer","enrollment":118},{"nctId":"NCT04556773","phase":"PHASE1","title":"A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2020-12-17","conditions":"Metastatic Breast Cancer","enrollment":138},{"nctId":"NCT03079011","phase":"PHASE3","title":"PAlbociclib and Circulating Tumor DNA for ESR1 Mutation Detection","status":"COMPLETED","sponsor":"UNICANCER","startDate":"2017-03-22","conditions":"Metastatic Breast Cancer","enrollment":1017},{"nctId":"NCT05041842","phase":"PHASE2","title":"Treatment With Tucatinib in Patients With an Isolated Brain Progression of a Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2021-12-17","conditions":"Metastatic Breast Cancer With a Isolated Brain Progression","enrollment":53},{"nctId":"NCT03147287","phase":"PHASE2","title":"Palbociclib After CDK and Endocrine Therapy (PACE)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2017-09-05","conditions":"Metastatic Breast Cancer","enrollment":220},{"nctId":"NCT03959891","phase":"PHASE1","title":"AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2019-05-30","conditions":"Breast Cancer","enrollment":77},{"nctId":"NCT04158362","phase":"PHASE3","title":"Endocrine Therapy With Abemaciclib or Chemotherapy as Initial Metastatic Treatment in ER+/HER2- Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2020-06-11","conditions":"Cancer Metastatic","enrollment":180},{"nctId":"NCT06208410","phase":"PHASE1, PHASE2","title":"A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors","status":"RECRUITING","sponsor":"Risen (Suzhou) Pharma Tech Co., Ltd.","startDate":"2024-01-11","conditions":"Advanced Solid Tumors","enrollment":306},{"nctId":"NCT05181033","phase":"PHASE2","title":"Lenvatinib+Letrozole Versus Fulvestrant in Metastatic ER+/HER2- Breast Cancer, Post Progression on Al + CDK4/6 Inhibitor","status":"RECRUITING","sponsor":"National University Hospital, Singapore","startDate":"2021-12-27","conditions":"Breast Cancer","enrollment":120},{"nctId":"NCT05251714","phase":"PHASE1, PHASE2","title":"CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Treadwell Therapeutics, Inc","startDate":"2022-05-27","conditions":"Advanced Solid Tumor, Breast Cancer","enrollment":44},{"nctId":"NCT05759949","phase":"PHASE1","title":"First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors","status":"COMPLETED","sponsor":"Relay Therapeutics, Inc.","startDate":"2023-03-29","conditions":"PIK3CA Mutation, Solid Tumor, Adult, HER2-negative Breast Cancer","enrollment":41},{"nctId":"NCT06957379","phase":"PHASE2","title":"Sirolimus for Injection (Albumin-bound) in Combination With Endocrine Therapy for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Who Have Failed Standard Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2024-02-29","conditions":"HR+/HER2- Advanced/Metastatic Breast Cancer","enrollment":78},{"nctId":"NCT06929325","phase":"PHASE3","title":"Sirolimus for Injection (Albumin-bound) Combined With Fulvestrant for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Previously Treated With CDK4/6 Inhibitors","status":"NOT_YET_RECRUITING","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2025-04","conditions":"HR+/HER2- Advanced/Metastatic Breast Cancer","enrollment":312},{"nctId":"NCT06525675","phase":"","title":"Study to Evaluate the Extended Overall Survival (OS) Data From PARSIFAL Study (The PARSIFAL-LONG Study)","status":"COMPLETED","sponsor":"MedSIR","startDate":"2022-07-18","conditions":"Metastatic Breast Cancer, Advanced Breast Cancer, Luminal Breast Cancer","enrollment":419},{"nctId":"NCT03238196","phase":"PHASE1","title":"Fulvestrant, Palbociclib and Erdafitinib in ER+/HER2-/FGFR-amplified Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Vanderbilt-Ingram Cancer Center","startDate":"2017-08-18","conditions":"Metastatic Breast Cancer","enrollment":35},{"nctId":"NCT05054751","phase":"PHASE3","title":"GB491 Combined With Fulvestrant for HR+ HER2- Locally Advanced or Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Genor Biopharma Co., Ltd.","startDate":"2021-09-10","conditions":"Locally Advanced or Metastatic Breast Cancer","enrollment":275},{"nctId":"NCT04539496","phase":"PHASE1, PHASE2","title":"A Phase I/II Study of XZP-3287 in Metastasis Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sihuan Pharmaceutical Holdings Group Ltd.","startDate":"2018-05-22","conditions":"Metastasis Solid Tumors, Advanced Breast Cancer","enrollment":402},{"nctId":"NCT01296555","phase":"PHASE1","title":"A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer","status":"TERMINATED","sponsor":"Genentech, Inc.","startDate":"2011-03-16","conditions":"Solid Cancers, Non-Hodgkin's Lymphoma","enrollment":674},{"nctId":"NCT04726332","phase":"PHASE1","title":"Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101)","status":"TERMINATED","sponsor":"Exelixis","startDate":"2021-02-10","conditions":"Neoplasm Malignant, Epithelial Ovarian Cancer, Triple Negative Breast Cancer","enrollment":52},{"nctId":"NCT06172322","phase":"PHASE1","title":"A Phase Ib/Ⅱ Study of NTQ1062 in Combination With Fulvestrant in Patients With Advanced HR Positive /HER-2 Negative Breast Cancer","status":"UNKNOWN","sponsor":"Nanjing Chia-tai Tianqing Pharmaceutical","startDate":"2023-12-28","conditions":"HR Positive/HER-2 Negative Breast Cancer","enrollment":42},{"nctId":"NCT06202261","phase":"PHASE1, PHASE2","title":"A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2023-04-13","conditions":"Metastatic Breast Cancer, Recurrent Breast Cancer, Advanced Malignancies","enrollment":154},{"nctId":"NCT05861830","phase":"PHASE3","title":"Dalpiciclib With Endocrine Therapy for Advanced Breast Cancer After CDK4/6 Inhibitor Failure (DAWNA-FES)","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2023-05-15","conditions":"Advanced Breast Cancer","enrollment":80},{"nctId":"NCT00278915","phase":"PHASE2","title":"Faslodex in McCune-Albright Syndrome","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-01-31","conditions":"Puberty, Precocious, McCune-Albright Syndrome","enrollment":30},{"nctId":"NCT05238831","phase":"EARLY_PHASE1","title":"SMMART Adaptive Clinical Treatment (ACT) Trial","status":"WITHDRAWN","sponsor":"OHSU Knight Cancer Institute","startDate":"2023-01-30","conditions":"Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Ovarian Carcinoma","enrollment":0},{"nctId":"NCT02792465","phase":"PHASE1","title":"A Study of Investigational Drug CFI-402257 in Patients With Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2016-11-11","conditions":"Advanced Solid Cancers, Breast Cancer","enrollment":52},{"nctId":"NCT05905341","phase":"PHASE1","title":"Study of PF-07224826, as a Single Agent or in Combination With Endocrine Therapy in Participants With Breast Cancer and Other Advanced Solid Tumors.","status":"WITHDRAWN","sponsor":"Pfizer","startDate":"2024-01-15","conditions":"Breast Cancer, Ovarian Cancer, Liposarcoma","enrollment":0},{"nctId":"NCT06074757","phase":"PHASE1","title":"Open Label, Sequential Dosing , Single Ascending Dose and Multiple Dose Safety Tolerability and Pharmacokinetic Study","status":"COMPLETED","sponsor":"Kashiv BioSciences, LLC","startDate":"2023-03-01","conditions":"Metastatic Breast Cancer","enrollment":48},{"nctId":"NCT05433480","phase":"PHASE3","title":"A Study of BPI-16350 in Combination With Fulvestrant in Patients With HR+ and HER2- Locally Advanced, Recurrent or Metastatic Breast Cancer","status":"UNKNOWN","sponsor":"Betta Pharmaceuticals Co., Ltd.","startDate":"2022-05-25","conditions":"Breast Cancer","enrollment":274},{"nctId":"NCT02761694","phase":"PHASE1","title":"Vevorisertib (ARQ 751) as a Single Agent or in Combination With Other Anti-Cancer Agents, in Solid Tumors With PIK3CA / AKT / PTEN Mutations (MK-4440-001)","status":"TERMINATED","sponsor":"ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)","startDate":"2016-06-26","conditions":"Cancer, Solid Tumors","enrollment":78},{"nctId":"NCT02756364","phase":"PHASE2","title":"Sapanisertib in Combination With Fulvestrant in Women With Advanced or Metastatic Breast Cancer After Aromatase Inhibitor Therapy","status":"COMPLETED","sponsor":"Calithera Biosciences, Inc","startDate":"2016-07-28","conditions":"Breast Neoplasms","enrollment":141},{"nctId":"NCT03386162","phase":"PHASE2","title":"SAFIR-PI3K A Phase II Randomized Maintenance Trial Comparing Alpelisib and Fulvestrant Versus Chemotherapy in PIK3CA Mutated Advanced Breast Cancer","status":"TERMINATED","sponsor":"UNICANCER","startDate":"2018-03-15","conditions":"Breast Cancer, PI3K, Alpelisib","enrollment":31},{"nctId":"NCT02626507","phase":"PHASE1","title":"Phase I Study of Combination of Gedatolisib With Palbociclib and Faslodex in Patients With ER+/HER2- Breast Cancer","status":"UNKNOWN","sponsor":"Hoffman Oncology","startDate":"2016-01","conditions":"Breast Cancer","enrollment":18},{"nctId":"NCT05191914","phase":"PHASE4","title":"Clinical Study of Fulvestrant Combined With Chidamide in the Treatment of Hormone Receptor-positive Advanced Breast Cancer Resistant to CDK4/6 Inhibitors","status":"UNKNOWN","sponsor":"Liaoning Cancer Hospital & Institute","startDate":"2022-02-07","conditions":"Breast Cancer","enrollment":20},{"nctId":"NCT02366130","phase":"PHASE2","title":"Trial of Ra-223 Dichloride in Combination With Hormonal Therapy and Denosumab in the Treatment of Patients With Hormone-Positive Bone-Dominant Metastatic Breast Cancer","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-02-11","conditions":"Breast Cancer","enrollment":45},{"nctId":"NCT04031885","phase":"PHASE4","title":"A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer","status":"TERMINATED","sponsor":"Eli Lilly and Company","startDate":"2019-08-14","conditions":"Metastatic Breast Cancer","enrollment":4},{"nctId":"NCT03324061","phase":"PHASE1","title":"Study to Evaluate the Safety, Tolerability, and PK of Fulvestrant After IM Administration","status":"COMPLETED","sponsor":"Eagle Pharmaceuticals, Inc.","startDate":"2017-11-30","conditions":"Pharmacokinetics","enrollment":600},{"nctId":"NCT03927456","phase":"PHASE3","title":"A Study of SHR6390 in Combination With Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer","status":"UNKNOWN","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2019-06-13","conditions":"Advanced Breast Cancer","enrollment":357},{"nctId":"NCT02569801","phase":"PHASE2","title":"A Study of GDC-0810 Versus Fulvestrant in Postmenopausal Women With Advanced or Metastatic Breast Cancer Resistant to Aromatase Inhibitor (AI) Therapy","status":"TERMINATED","sponsor":"Genentech, Inc.","startDate":"2015-12-04","conditions":"Breast Cancer","enrollment":71},{"nctId":"NCT02088684","phase":"PHASE1","title":"Study of LEE011 With Fulvestrant and BYL719 or BKM120 in Advanced Breast Cancer","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-05-19","conditions":"Breast Cancer","enrollment":70},{"nctId":"NCT04526028","phase":"","title":"Palbociclib in Combination With Fulvestrant Versus Fulvestrant in Advanced Breast Cancer: A Real-world Study in China","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2019-09-13","conditions":"Breast Cancer, Fulvestrant, Palbociclib","enrollment":612},{"nctId":"NCT03236974","phase":"PHASE1","title":"Study to Compare the Effects of AZD9496 vs Fulvestrant in Breast Cancer.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-10-05","conditions":"Postmenopausal Women With ER+ HER2- Primary Breast Cancer","enrollment":49},{"nctId":"NCT03024580","phase":"PHASE2","title":"A Study Evaluating Megestrol Acetate Modulation in Hormone Receptor Positive Advanced Breast Cancer","status":"UNKNOWN","sponsor":"Instituto Nacional de Cancer, Brazil","startDate":"2017-03-06","conditions":"Breast Neoplasm","enrollment":20},{"nctId":"NCT03925233","phase":"","title":"Breast Cancer Treatment Based on Organ-like Culture","status":"UNKNOWN","sponsor":"Xijing Hospital","startDate":"2019-01-02","conditions":"Breast Cancer Organoids","enrollment":300},{"nctId":"NCT02000193","phase":"PHASE2","title":"Maintenance Hormone Therapy for Postmenopausal HR Positive Advanced Breast Cancer","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2013-11","conditions":"Breast Cancer","enrollment":58},{"nctId":"NCT02116803","phase":"PHASE2, PHASE3","title":"An Open Label Multi-center Extension Study to Evaluate Long-term Safety/ Tolerability of Dovitinib in Patients With Solid Tumors Who Continue to Receive Treatment With Dovitinib (TKI258) in Novartis-sponsored Single Agent Dovitinib Studies Which Fulfilled the Requirements for the Primary Objective","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-05-28","conditions":"Solid Tumors","enrollment":12},{"nctId":"NCT00932152","phase":"PHASE2","title":"Fulvestrant and Anastrozole as Consolidation Therapy in Postmenopausal Women With Advanced Non-small Cell Lung Cancer","status":"TERMINATED","sponsor":"University of Pittsburgh","startDate":"2010-09","conditions":"Non-small Cell Lung Cancer, Postmenopausal Women","enrollment":3},{"nctId":"NCT02394496","phase":"PHASE3","title":"Overcoming Endocrine Resistance in Metastatic Breast Cancer","status":"UNKNOWN","sponsor":"Consorzio Oncotech","startDate":"2007-11","conditions":"Metastatic Breast Cancer","enrollment":396}],"_emaApprovals":[{"date":"","name":"Fulvestrant Injectable Product","status":"Authorised","regulator":"EMA"}],"_faersSignals":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"molecularData":{"oral":false,"chemblId":"CHEMBL4760678","moleculeType":"Unknown","molecularWeight":"606.78"},"_patentsChecked":true,"_warningLetters":[{"date":"03/28/2023","subject":"11/07/2022\tTodos Medical Ltd aka Todos Medical USA Inc\tCenter for Food Safety and Applied Nutrition"},{"date":"03/27/2026","subject":"Feedback form"}],"crossReferences":{"chemblId":"CHEMBL4760678"},"formularyStatus":[],"_approvalHistory":[],"_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"recentPublications":[],"_drugWebsiteChecked":true,"_healthCanadaChecked":true,"companionDiagnostics":[],"_genericFilersChecked":true,"genericManufacturerList":[],"phase":"marketed","status":"approved","companyName":"Pfizer","companyId":"pfizer","modality":"peptide","firstApprovalDate":"","enrichmentLevel":3,"visitCount":5,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"EU","regulator":"EMA","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":3,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:57:22.132470+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}